孟鲁司特钠治疗儿童咳嗽变异性哮喘的效果观察

目的:探讨孟鲁司特钠治疗儿童咳嗽变异性哮喘的临床治疗效果。方法:回顾性分析90例咳嗽变异性哮喘患儿,随机分为观察组45例和对照组45例,对照组采用的治疗方法为口服盐酸丙卡特罗片和氯雷他定片,观察组的治疗方法是在对照组基础上口服孟鲁司特钠,应用治疗为3个月,比较两组的临床治疗效果。结果:观察组的总有效率显著高于对照组的总有效率,差异有统计学意义(P<0.05)。结论:孟鲁司特钠在治疗儿童咳嗽变异性哮喘方面,具有疗效显著、不良反应少、依从性好等特点,值得临床推广使用。     

Characterization of sequence variations within HPV16 isolates among Indian women: prediction of causal role of rare non-synonymous variations within intact isolates in cervical cancer pathogenesis

We re-sequenced HPV16 genome (~6 kb) implicated in cervical carcinogenesis (LCR, E2, E5, E6, E7, L1, L2) to prioritize sequence variants for functional validation as biomarkers, using CaCx cases (n=74) and asymptomatic controls (n=24). Of the nucleotide variations recorded (n=271), non-synonymous changes in L2 region were significantly higher (p=0.005) among cases (2.67%) compared to controls (1.27%). Using SIFT database, 29 non-synonymous changes (frequency=0.01-0.03) predicted as deleterious to protein functions were identified. Haplotype analysis considering 110 polymorphic variations (frequency> or =0.05) within intact viral isolates (53 CaCx cases and 21 controls) using NETWORK software, confirmed Asian-American (AA, 14.86%) and European (E, 85.14%) variants, differing at 78 positions. The E-variants portrayed thirty-six haplotypes, of which, E-12 was most prevalent within cases (38.1%; 16/42) and controls (28.57%; 6/21) harboring polymorphic variations at 10 positions, in contrast to HPV16R. Cases of the E-12 haplotype harbored 7 deleterious mutations distributed within L1 (n=1), E2 (n=1), E5 (n=1), and L2 (n=4), while none within similar controls. Thus rare deleterious variations within genes implicated in productive infection over the E-12 haplotype background of intact HPV16 isolates might be of causal relevance for CaCx development.     

RhCE抗原基因分型和表型不一致与等位基因变异的相关性研究

目的 探讨变异RhCE抗原的分子背景及RHCE基因的遗传学特征与基因多态性.方法 采用单克隆抗-C、-c、-E和-e试剂检测10373例RhD阳性和635例RhD阴性献血者的RhCE表型;选择942例标本PCR-SSP技术做RHCE基因分型,对基因分型与血清学分型不一致标本采用PCR-SSP检测22个主要RHCE变异等位基因,部分RHCE等位基因采用测序技术鉴定.结果 共有54例标本(占94.27％)基因分型结果与血清学表型结果不一致,经PCR-SSP检测出22种与弱表达抗原相关的RHCE等位基因变异体,经血清学复检有36例标本RhCE抗原存在弱反应或极弱反应.结论 在血清学检测时表达弱反应的RhCcEe抗原标本中检出多种RHCE等位基因类型,变异的等位基因可以影响基因分型预测血型抗原的准确性:RhCE表型和基因型不一致的原因可能由变异的等位基因或未发现的等位基因引起.     

Normal and variant pelvic anatomy on MRI

The superior tissue contrast and flexible imaging planes afforded by magnetic resonance imaging (MRI) versus competing technologies permit optimal depiction of the pelvic viscera. Targeted protocols developed for specific pelvic visceral organs highlight important anatomic features that may not be imaged by other modalities. Therefore, a solid understanding of normal and variant pelvic anatomy is crucial for appropriate interpretation of pelvic MRI studies. This article discusses the protocol strategies and relevant anatomy with commonly encountered anatomical variants in a segmented/organ-specific manner, using gender as a broad split given the substantial variance in relevant organs.     

重症医学科重度子痫前期产妇围手术期临床路径的应用

目的 评价综合重症医学科(ICU)开展重度子痫前期产妇围手术期临床路径(CP)的效果,并分析其变异情况以促进质量改进.方法 比较福建医科大学附属第二医院ICU内实行CP前1年(2009年1月至12月,14例)和实施CP后1年(2010年1月至12月,22例)收治的重度子痫前期产妇ICU停留时间、住院费用、并发症发生率、病死率以及术后前3 d血压控制的总有效率.结果 与实施CP前1年组比较,实施CP后1年组ICU停留时间(h)明显缩短(65.5±24.9比86.3±28.2,t=2.321,P＜0.05),ICU住院费用(元)明显减少(6 463.6±1 838.2比8 136.5±2 142.8,t=2.496,P＜0.05),并发症发生率有所下降(36.4%比42.8%,x2=0.100,P＞0.05);血压控制的总有效率术后1 d、2 d明显提高(1 d:59.1%比14.3%,2 d:86.4%比50.0%,均P＜0.05),而术后3 d则无明显差异(95.4%比85.7%,P＞0.05).实施CP前1年组死亡1例,实施CP后1年组无死亡.结论 通过对重度子痫前期产妇围手术期实施CP管理,降低了患者的医疗负担,促进了医疗质量持续改进.

Abstract：

Objective To evaluate the effect of implementation of perioperative clinical pathway (CP)for severe preeclampsia patients in intensive care unit (ICU), and to discuss variation factors in order to improve clinical quality. Methods Thirty-six patients treated in ICU in the Second Clinical Hospital of Fujian Medical University were divided into two groups according to time of 1 year before implementation of CP (from January to December in 2009, n = 14) and 1 year after implementation of CP (from January to December in 2010, n = 22). The length of stay in ICU, cost of hospitalization, occurrence of major complications and mortality, as well as the total effective rate of control of blood pressure in the first 3 days after operation were compared. Results Compared with the group of patients of 1 year before implementation of CP, in the group of patients of 1 year after implementation of CP, the length of stay in ICU (hours) was significantly shorter (65. 5 ±24. 9 vs. 86. 3 ±28. 2, t = Z. 321, P＜0. 05), the cost of hospitalization (yuan) was significantly lower (6 463. 6±1 838.2 vs. 8 136. 5±2 142.8, r = 2. 496, P＜ 0. 05), the occurrence rate of major complications was lower (36. 4% vs. 42. 8%, x2 = 0. 100, P＞0. 05), the total effective control rate of blood pressure was significant improved on the 1st and the 2nd postoperative day (1 day: 59. 1 % vs. 14. 3%, 2 days: 86. 4% vs. 50. 0%, both P＜0. 05), but there was no significant change on the 3rd postoperative day (95. 4% vs. 85. 7%, P＞0. 05). One patient died before the application of CP,and none after its application. Conclusion These results suggested that it was beneficial to implement the program in preeclampsia patients to improve medical quality.     

ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria

This paper is the first in a series providing updated guidance on the definition, evaluation and management of people with a Cystic Fibrosis Transmembrane conductance Regulator (CFTR)-Related Disorder (CFTR-RD). The need for this update relates to more precise characterisation of CFTR gene variants and improved assessment of CFTR protein dysfunction. The exercise is co-ordinated by the European CF Society Standards of Care Committee and Diagnostic Network Working Group and involves stakeholder engagement. This first paper was produced by a core group using an extensive literature review and papers graded for their quality. Subsequent wider stakeholder agreement was achieved.The definition of a CFTR-RD remains “a clinical condition with evidence of CFTR protein dysfunction that does not fulfil the diagnostic criteria for CF”. Clearer guidance on CFTR dysfunction and relevant CFTR variants will be provided. Thresholds for clinical presentations are presented and the paradigm that pathobiological processes may be evident in more than one organ is agreed. In this paper we reflect on the early patient journey, highlighting that CF specialists as well as other relevant specialists should be involved in the care of people with a CFTR-RD.